Novo Nordisk Faces Double Departures: GLP-1 Expert Retires as Obesity Leader Joins Boehringer Ingelheim on April 13, 2026 Boehringer Ingelheim Glucagon-Like Peptide 1 leader Novo Nordisk Obesity Research Personnel Retirement +
Chinese Biotechs Shed Fast-Follower Reputations as Innovation Surges in 2025 on November 13, 2025 biopharma China Chinese Language Clinical Trials drug candidates global drug pipeline innovation leader R&D regulatory reforms +